Literature DB >> 21887454

Lymphocyte function following radioiodine therapy in patients with thyroid carcinoma.

V Barsegian1, S P Müller, P A Horn, A Bockisch, M Lindemann.   

Abstract

AIM: Since the nuclear disaster in Fukushima has raised great concern about the danger of radioactivity, we here addressed the question if the therapeutic use of iodine 131, the most frequently applied radionuclide, was harmful to immune function in patients. It was our aim to define for the first time in a clinical setting how radioiodine therapy alters anti-microbial immune responses. PATIENTS,
METHODS: In 21 patients with thyroid carcinoma anti-microbial lymphocyte responses were assessed by lymphocyte transformation test and ELISpot - measuring lymphocyte proliferation and on a single cell level production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10) - prior to therapy, at day 1 and day 7 post therapy.
RESULTS: Proliferative lymphocyte responses and interferon-γ production after in vitro stimulation with microbial antigens were significantly (p < 0.05) increased at day 1 vs. pre therapy, and returned to pre therapy levels at day 7. On the contrary, at day 1 interleukin-10 production was significantly (p < 0.05) reduced. Thus, we observed a short-term increase in pro-inflammatory immune responses. However, T lymphocyte responses were in the range of healthy controls at all three time points.
CONCLUSION: Thyroid carcinoma patients receiving radioiodine therapy do not display any sign of immunosuppression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21887454     DOI: 10.3413/nukmed-04241108

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  2 in total

1.  Lymphocyte function following radium-223 therapy in patients with metastasized, castration-resistant prostate cancer.

Authors:  Vahé Barsegian; Stefan P Müller; Daniel Möckel; Peter A Horn; Andreas Bockisch; Monika Lindemann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-10-08       Impact factor: 9.236

Review 2.  Thyroid Cancer and COVID-19: Prospects for Therapeutic Approaches and Drug Development.

Authors:  Na Qu; Zongguang Hui; Zhixin Shen; Chengxia Kan; Ningning Hou; Xiaodong Sun; Fang Han
Journal:  Front Endocrinol (Lausanne)       Date:  2022-05-04       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.